Rectal Cancer Treatment Outcome Predictions

Beck, J. et al. Comprehensive analyses of rectal cancer genomes to reveal copy number variations as potential predictor of induction therapy efficacy. J ClinOncol 32, 2014 (suppl; abstr e14549).

Genome profiling of individual tumors is provided by high-throughput sequencing and is about to enter routine clinical practice with impact on treatment decisions and tumor classification (NIH [2014] The Cancer Genome Atlas).

By |2018-08-24T09:33:56+00:00May 11th, 2017|Peer-reviewed medical publications|0 Comments

HPV Genotyping and Treatment Outcome Predictions

Urnovitz, HB et al. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS). J ClinOncol 32:5s, 2014 (suppl; abstr 6072).

The detection of novel HPV mutations and CNI analysis in a single NGS run on HPV-related diseases provides important information into viral-host dynamics while generating biomarkers that can be correlated with treatment outcomes.

By |2018-08-24T09:33:56+00:00May 10th, 2017|Peer-reviewed medical publications|0 Comments

Animal Model for MRD in Breast Cancer

Beck, J. et al. Structural variation in mammary carcinomas and their detection in cell-free plasma DNA. PLOS One 2013 (10.1371/journal.pone.0075485).

Mammary tumors are the most frequent cancers in female dogs exhibiting a variety of histopathological differences. There is lack of knowledge about the genomes of these common dog tumors. Five tumors of three different histological subtypes were evaluated.

By |2018-08-24T09:33:56+00:00May 8th, 2017|Peer-reviewed medical publications|0 Comments

Breast Cancer cfDNA with NGS

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.

Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.

By |2018-08-24T09:33:57+00:00May 5th, 2017|Peer-reviewed medical publications|0 Comments

Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

By |2019-03-21T09:37:59+00:00November 14th, 2016|Other publications|0 Comments

Advanced Cancer Diagnostics Showcasing at 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: Second Opinion CNI Prostate Cancer Test, Second Opinion CNI Breast Cancer Test, CNI Monitor Test.

By |2017-07-05T09:05:36+00:00November 3rd, 2016|Events|0 Comments

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting 2016 on 5 June 2016 at McCormick Place in Chicago, Illinois. The abstract and poster presentation describe the work conducted by independent oncologists in a blinded [...]

By |2019-03-21T09:38:00+00:00November 3rd, 2016|Events|0 Comments

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

Chronix Biomedical

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies...

By |2019-03-21T09:38:00+00:00November 3rd, 2016|Chronix news|0 Comments